Nathoe H M, Doevendans P A F M
Universitair Medisch Centrum Utrecht, afd. Cardiologie, Postbus 85.500, 3508 GA Utrecht.
Ned Tijdschr Geneeskd. 2005 Jul 30;149(31):1740.
Treating all persons above 55 years of age with a polypill for primary and secondary cardiovascular-disease prevention may reduce cardiovascular events by more than 80%. This strategy is expected to be cost-effective and the associated risk of side effects is estimated to be low.
用复方制剂治疗所有55岁以上人群以进行心血管疾病的一级和二级预防,可能会使心血管事件减少80%以上。这一策略预计具有成本效益,且副作用的相关风险估计较低。